Sino Biopharmaceutical (HKG:1177) received positive Phase III clinical trial results for its non-small cell lung cancer (NSCLC) drug, according to a Wednesday filing with the Hong Kong bourse.
Benmelstobart Injection is sometimes used with Anlotinib Capsules for treating a specific type of lung cancer (Stage III non-small cell lung cancer) that cannot be removed or has advanced locally.
The interim analysis of the drug shows "primary study endpoint progression-free survival (PFS) has met the protocol's predefined superiority threshold."
The pharmaceutical has contacted China's Centre for Drug Evaluation about submitting a marketing application.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。